https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Hematologic Highlights from ASCO 2025: CARTITUDE-1 and STARGLO

Hematologic Highlights from ASCO 2025: CARTITUDE-1 and STARGLO

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

administrator

Related Articles